The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line

Leukemia

Volumn 9, Issue 2, 1995, Pages 295-301

  Oda, Tsukasa ^a   Tamura, Shu ^a   Matsuguchi, Tetsuya ^b   Griffin, James D ^b   Druker, Brian J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

BCR ABL; CML; Philadelphia chromosome

Indexed keywords

CHIMERIC PROTEIN; GROWTH FACTOR; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ARTICLE; BONE MARROW CULTURE; CELL GROWTH; CHROMOSOME 22; CHROMOSOME 9; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; EXON; GENE FUSION; GENE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION;

EID: 0028899930     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497-1501.
2. Rowley JD. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine, fluorescence and Giemsa staining. Nature 1973;243:290-293.
3. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G. Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukaemia. Nature 1983;306:239-242.
4. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts von Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M, Heisterkamp N, Stephenson JR, Groffen J. Translocation of c-abl correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature 1983; 306:277-280.
5. Daley GQ, Baltimore D. Transformation of an interleukin-3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci USA 1988;85:9312-9316.
6. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 unmasks associated tyrosine kinase activity. Cell 1984;37:1035-1042.
7. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the p210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 1987;84:6558-6562.
8. Sefton BM, Hunter T, Raschke WC. Evidence that the Abelson virus protein functions in vivo as a protein tyrosine kinase that phosphorylates tyrosine. Proc Natl Acad Sci USA 1981; 78:1552-1556.
9. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-830.
10. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 1990;87:6649-6653.
11. Gishizky ML, Johnson-White J, Witte ON. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci USA 1993;90:3755-3759.
12. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, Gishizky ML. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75:175-185.
13. Puil L, Liu J, Gish G, Mbamalu G, Botwell D, Pelicci PG, Arlinghaus R, Pawson T. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994;13:764-773.
14. Matsuguchi T, Salgia R, Hallek M, Eder M, Druker B, Ernst T, Griffin JD. SHC phosphorylation in myeloid cells is regulated by GM-CSF, IL-3, and steel factor and is constitutively increased by p210BCR-ABL. J Biol Chem 1994;269:5016-5021.
15. Tauchi T, Boswell HS, Leiboweitz D, Broxmeyer HE. Coupling between p210bcr-abl and She and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med 1994;179:167-175.
16. Druker B, Okuda K, Matulonis U, Salgia R, Roberts T, Griffin JD. Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood 1992;79: 2215-2220.
17. BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene 1994;9:149-156.
18. Lu D, Liu J, Campbell M, Guo JQ, Heisterkamp N, Groffen J, Canaani E, Arlinghaus R. Tyrosine phosphorylation of p160 BCR by p210 BCR-ABL. Blood 1993;82:1257-1263.
19. Ernst TJ, Slattery KE, Griffin JD, p210Bcr/Abl and p160v-abl induce an increase in the tyrosine phosphorylation of p93c-fes. J Biol Chem 1994;269:5764-5769.
20. ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken J-W, Heisterkamp N, Groffen J. Cellular interactions of CRKL, an SH2-SH3 adapator protein. Cancer Res 1994;54:2563-2567.
21. Oda T, Heaney C, Hagopian J, Okuda K, Griffin JD, Druker BJ. CRKL is the major tyrosine phosphorylated protein in neutrophils from patients with chronic myleogenous leukemia. J Biol Chem 1994;269:22925-22928.
22. Druker BJ, Roberts TM. Generation of a large library of point mutations in polyoma middle T antigen. Nucleic Acids Res 1991;19:6855-6861.
23. Druker BJ, Sibert L, Roberts TM. Polyomavirus middle T-antigen NPTY mutants. J Virol 1992;66:5770-5776.
24. Greenberger JS, Sakakeeny MA, Humphries RK, Eaves CJ, Eckner RJ. Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines. Proc Natl Acad Sci USA 1983;80:2391-2395.
25. Schiff-Maker L, Burns MC, Konopka JB, Clark S, Witte ON, Rosenberg N. Monoclonal antibodies specific for v-abl- and c-abl-encoded molecules. J Virol 1986;57:1182-1186.
26. Kanakura Y, Druker B, Cannistra SA, Furukawa Y, Torimoto Y, Griffin JD. Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves a common set of cytoplasmic proteins. Blood 1993;76:706-715.
27. Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD. IL-3 and p210BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol 1993;21:1460-1466.
28. Hirai H, Varmus HE. Site-directed mutagenesis of the SH2- and SH3-coding domains of c-src produces varied phenotypes, including oncogenic activation of p60c-src. Mol Cell Biol 1990;10:1307-1318.
29. Mayer BJ, Jackson PK, Van Etten RA, Baltimore D. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol Cell Biol 1992;12:609-618.
30. Muller AJ, Pendergast AM, Parmar K, Havlik MH, Rosenberg N, Witte ON. En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase. Proc Natl Acad Sci USA 1993;90:3457-3461.
31. McWhirter JR, Wang JYJ. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 1993;12: 1533-1546.
32. Seidel-Dugan C, Meyer BE, Thomas SM, Brugge JS. Effects of SH2 and SH3 deletions on the functional activities of wild-type and transforming variants of c-src. Mol Cell Biol 1992;12:1835-1845.
33. Pawson T, Gish GD. SH2 and SH3 domains: from structure to function. Cell 1992;71:359-362.
34. Waksman G, Shoelson SE, Pant N, Cowburn D, Kuriyan J. Binding of a high-affinity phosphotyrosyl peptide to the src SH2 domain: crystal structures of the complexed and peptide-free forms. Cell 1993;72:779-790.
35. Booker GW, Breeze AL, Downing AK, Panayotou G, Gout I, Waterfield MD, Campbell ID. Structure of an SH2 domain of p85α subunit of phosphatidylinositol-3-OH kinase. Nature 1992; 358:684-687.
36. McWhirter JR, Galasso DL, Wang JYJ. A coiled-coiled oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993;13:7587-7595.
37. Mayer BJ, Baltimore D. Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the ABL tyrosine kinase. Mol Cell Biol 1994;14:2883-2894.
38. v-src prevent association with the detergent-insoluble cellular matrix. Mol Cell Biol 1991;11:1207-1213.
39. Nemeth SP, Fox LG, DeMarco M, Brugge JS. Deletions within the amino-terminal half of the c-src gene product that alter the functional activity of the protein. Mol Cell Biol 1989;9:1109-1119.
40. De Clue JE, Martin GS. Linker insertion-deletion mutagenesis of the v-src gene: isolation of host- and temperature-dependent mutants. J Virol 1989;63:542-554.
41. Pendergast AM, Gishizky ML, Havlik MH, Witte ON. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol 1993;13:1728-1736.